00_transportation_isolation_system_1

Results released from first clinical trial using Danoprevir to treat COVID-19

pharmafile | March 25, 2020 | News story | Research and Development COVID, COVID-19, Wuhan, china coronavirus, coronavirus 

The first clinical trial using danoprevir (Ganovo) in treating COVID-19 has released its results, showing that it is safe and well tolerated in patients.

The data was published in medRxiv, and the trial saw 19 patients in a 4 to 12-day treatment of danoprevir combined with ritonavir.  After this initial treatment, the first negative test occurred at a median of 2 days and ranged from 1 to 8 days. CT scans revealed that the obvious absorption rate occurred at a median of 3 days ranging from 2 to 4 days.

Eleven patients were discharged from the hospital after they met all four of these conditions: normal body temperature for 3 days, improved respiratory symptoms, lung imaging showing absorption and recovery of acute exudative lesion and two consecutive RT-PCR negative tests of SARS-CoV-2 nucleotide acid.

Advertisement

Dr. Jinzi  Wu, Chairman and CEO of Ascletis, commented on the results: “We are pleased that the first clinical study using Ganovo®(danoprevir) to treat COVID-19 patients was published in medRxiv. Ascletis is proud of repurposing our HCV drug, danoprevir, as a potential therapeutic option for COVID-19.”

Conor Kavanagh

Related Content

covid_cell

COVID-19 vaccine eligibility creates challenges for UK pharmacies

Pharmacists across England have reported widespread confusion among patients attempting to book COVID-19 vaccination appointments …

Prescriptions image

Mental health medicine use in England reaches record high, NHSBSA report reveals

According to new data published by the NHS Business Services Authority (NHSBSA), mental health prescriptions …

Vaccine image

FDA approves Moderna’s Spikevax for children at increased risk of COVID-19

Moderna has been granted US Food and Drug Administration (FDA) approval for its COVID-19 vaccine, …

The Gateway to Local Adoption Series

Latest content